| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Intangible asset, net | 2,002,969 | |||
| Prepaid expenses and other current assets | 112,659 | |||
| Cash and cash equivalents | 12,361,690 | |||
| Accounts and other receivable | 286,743 | |||
| Total current assets | 12,761,092 | |||
| Right-of-use assets | 0 | |||
| Long-term deposits | 40,739 | |||
| Total assets | 14,804,800 | |||
| Accumulated deficit | -63,645,218 | |||
| Preferred shares-Series B1Preferred Stock | 8,168,063 | |||
| Preferred shares-Series A1Preferred Stock | 1,054,735 | |||
| Capital shares authorized unlimited common shares without par value issued and outstanding 7,022,678 common shares (september 30, 2024 - 3,247,389) | 54,271,112 | |||
| Additional paid-in capital | 14,406,511 | |||
| Accumulated other comprehensive loss | -123,077 | |||
| Total shareholders' equity | 14,132,126 | |||
| Short-term right-of-use lease liabilities | 0 | |||
| Accounts payable and accrued liabilities | 672,674 | |||
| Total current liabilities | 672,674 | |||
| Total liabilities and shareholders' equity | 14,804,800 | |||
Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. (EDSA)